Antimicrobial compositions

Abstract

What is described herein are antimicrobial compositions which are defined blends of a 1,2-diol and phenoxyethanol which show broad activity against bacteria, fungi and mold spores. This activity is potentiated by the addition thereto of small amounts of a co-biocide for which the blend acts as a delivery system for the otherwise water-insoluble co-biocide.

Description

BACKGROUND OF THE INVENTION

1. Field of the Invention

This invention relates to antimicrobial compositions, and, more particularly, to a defined blend of a 1,2-diol and phenoxyethanol, optionally with a co-biocide, which compositions show broad activity against bacteria, fungi and mold spores.

2. Description of the Prior Art

Personal care products come in many different forms. They include creams, lotions, pastes, liquids, aerosols, shampoos, gels, wipes, bars, sticks, powders and granules any or all of which are intended for topical application to the skin including the scalp and the mucosa including the lips.

The products are generally designed to have a substantial shelf life. The products need to be manufactured at one site, transported possibly over a considerable distance to a depot or other storage facility prior to further transport to a point of sale. The product may then spend considerable time on a retailer's shelf prior to purchase and further storage by the user whether for individual use or use in, for example, a hotel, workplace, institution or the like. All of such storage will take place under uncontrolled conditions including considerable variation in temperature.

In order to keep bacterial and fungal growth in such products at an acceptable level it is conventional practice for the products to contain a preservative. Many preservatives are available. The appropriate preservative has to be selected with regard to its efficacy and its acceptability to contact with human or animal skin. With regard to its acceptability there are in many countries laws and regulations governing the maximum permitted content of preservative in products intended for human use due to their possible toxic or otherwise harmful effect.

The need to control microbiological growth in personal care products is known to be particularly acute in water based products such as non-ionic oil-in-water emulsions and in pre-impregnated wipes such as baby wipes.

For example, U.S. Pat. No. 6,607,738 described a preservative system of iodopropynyl butyl carbamate (IPBC) and phenoxyethanol (PE) in a weight ratio of 1:90 to 1:400 for use in personal care products.

U.S. Pat. No. 5,516,510 also disclosed deodorizing active ingredients to reduce the unpleasant odor caused by microorganisms which comprised a glycerin monoalkyl ether in combination with an astringent and/or a naturally occurring deodorant.

EP 1206933 described a preservative composition of caprylyl glycol (1,2-octanediol) and iodopropynyl butyl carbamate in a weight ratio of 0.1 to 500.

U.S. Pat. No. 5,733,362 was directed to a bacterial composition of 2-methyl-4,5-trimethylene-4-isothiazoline-3-on; 3-iodo-2-propynyl butyl carbamate and 2-phenoxyethanol.

EP 1238651 described that the activity of preservative mixtures of iodopropynyl butyl carbamate and phenoxyethanol, in a weight ratio of 1:90 to 1:200, preferably 1:100, can be potentiated by adding caprylyl glycol thereto, in a weight ratio of the latter to the mixture of 0.1 to 500, preferably 1:55. Thus the formulation of caprylyl glycol, iodopropynyl butyl carbamate and phenoxyethanol had weight ratios of each of 55:1:100 to 200:1:400, respectively. The personal care formulations contained 0.1-30% caprylyl glycol, preferably 0.5%; with 0.001-1% IPBC, preferably 0.001-0.01%; and with phenoxyethanol of 0.1-3%, preferably 0.5-1%.

JP Application No. 11045504 described an antiseptic microbicide and compositions thereof which contained a 1,2-alkane diol. These compositions effectively reduced the required dosage of conventional antiseptic microbicides such as paraben, benzoic acid and the like. The 1,2-alkane diol therein could be blended with a photosensitizer, benzoic acid or its salt, phenoxyethanol or 4-isopropyl-3-methylphenol. However, there was no disclosure of suitable blends of 1,2-alkane diol and phenoxyethanol at predetermined weight ratios and HLB values, which could deliver water insoluble biocides such as IPBC into aqueous personal care systems at a relatively high concentration of such biocides.

These and other prior art references in this field were concerned with the problem that many are antibacterials such as IPBC have limited aqueous solubility in personal care systems; particularly at the high concentrations necessary for effective antimicrobial activity. Thus, at very low concentrations they remain in solution but do not contribute as much activity as desired for these products.

Accordingly, it is desired to provide a blend of 1,2-diol and phenoxyethanol at a predetermined ratio and HLB value which can deliver water insoluble biocides into an aqueous personal care system at relatively high concentrations thereby providing more effective preservative activity in such systems.

SUMMARY OF THE INVENTION

What is described herein is an antimicrobial composition which is active against bacteria, yeast and mold spores, consisting essentially of, by wt.

(a) 40-60% of a 1,2-diol selected from the group consisting of 1,2-pentanediol, 1,2-hexanediol and 1,2-octanediol;

(b) 40-60% of phenoxyethanol; and

(c) 0-10% of a co-biocide selected from the group consisting of sorbic acid, benzoic acid, dibromodicyanobutane, iodopropynyl butyl carbamate and 1,2-benzisothiazolin-3-one.

A preferred antimicrobial composition of the invention includes (c) sorbic acid and/or 1% iodopropynyl butyl carbamate.

Most preferred antimicrobial compositions herein are those wherein (a) is about 44% and (b) is about 56%.

Also preferred are antimicrobial compositions wherein (c) is sorbic acid present in an amount of about 5-7% of the composition, or IPBC present in an amount of 1.25-1.50%.

Preferred antimicrobial compositions of the invention include those wherein (a) is 41-42%, (b) is 52-53%; and (c) is sorbic acid 5-7%; and (a) is 43.3; (b) is 55.3; and (c) is IPBC 1.4%.

The invention also encompasses personal care products which include the antimicrobial composition described above, preferably wherein the antibacterial composition is present in an amount of 0.1-2% by weight of the product, most preferably 0.5-1.5%.

DETAILED DESCRIPTION OF THE INVENTION

In accordance with the invention, there is provided herein an antimicrobial composition which is active against bacteria, yeast and mold spores, consisting essentially of, by wt.

(a) 40-60% of a 1,2-diol selected from the group consisting of 1,2-pentanediol, 1,2-hexanediol and 1,2-octanediol;

(b) 40-60% of phenoxyethanol; and

(c) 0-10% of a co-biocide selected from the group consisting of sorbic acid, benzoic acid, dibromodicyanobutane, iodopropynyl butyl carbamate and 1,2-benzisothiazolin-3-one.

Preferably the antimicrobial composition includes (c) sorbic acid and/or 1% iodopropynyl butyl carbamate.

Most preferably, the antimicrobial composition includes (a) about 44% and (b) about 56%, and, optionally, (c) is sorbic acid, present in an amount of about 5-7% of the composition, or (c) is IPBC present in an amount of 1.25-1.50%.

Most preferably, it is an antimicrobial composition wherein (a) is 41-42%, (b) is 52-53%; and (c) is sorbic acid 5-7%; most preferably, wherein (a) is 43.3; (b) is 55.3; and (c) is IPBC 1.4%.

Personal care products particularly utilize the antimicrobial composition, preferably, wherein the antibacterial composition is present in an amount of 0.1-2% by weight of the product, most preferably, 0.5-1.5%.

The invention will now be described in more detail by the following challenge test examples on the invention formulations.

Example 1

ANTIMICROBIAL: 1,2-Octanediol/Phenoxyethanol (40/60 wt. ratio)
PRODUCT BASE: Screening emulsion (Standard Emulsion)
TEST
ORGANISMS	INOCULUM (0 hours)	REINOCULUM (21 days)
Staph aureus 6538	1.9 × 106 cfu/ml	1.2 × 106 cfu/ml
E. coli 8739	4.6 × 106 cfu/ml	2.1 × 106 cfu/ml
P. aeruginosa 9027	1.7 × 106 cfu/ml	2.1 × 106 cfu/ml
B. cepacia 25416	2.5 × 106 cfu/ml	2.0 × 106 cfu/ml
C. albicans 10231	2.7 × 106 cfu/ml	9.0 × 105 cfu/ml
A. niger 16404	3.0 × 105 cfu/ml	1.0 × 105 cfu/ml
TEST	ASSAY INTERVALS
ORGANISMS	48 HRS	7 D	14 D	21 D	28 D
USE LEVEL: 0.5%
Staph. aureus 6538	<10	<10	<10	<10	<10
E. coli 8739	<10	<10	<10	<10	<10
P. aeruginosa 9027	<10	<10	<10	<10	<10
B. cepacia 25416	<10	<10	<10	<10	<10
C. albicans 10231	2.2E5	<10	<10	<10	<10
A. niger 16404	5.5E5	2E4	3.8E2	6E1	6.6E3
USE LEVEL: 1.0%
Staph. aureus 6538	<10	<10	<10	<10	<10
E. coli 8739	<10	<10	<10	<10	<10
P. aeruginosa 9027	<10	<10	<10	<10	<10
B. cepacia 25416	<10	<10	<10	<10	<10
C. albicans 10231	<10	<10	<10	<10	<10
A. niger 16404	1.4E5	<10	<10	<10	<10

Example 2

ANTIMICROBIAL: 1,2-Octanediol/Phenoxyethanol (40/60)
PRODUCT BASE: Nonionic emulsion
TEST
ORGANISMS	INOCULUM (0 hours)	REINOCULUM (21 days)
Staph aureus 6538	1.3 × 106 cfu/ml	8.0 × 106 cfu/ml
E. coli 8739	3.9 × 106 cfu/ml	4.8 × 106 cfu/ml
P. aeruginosa 9027	2.5 × 106 cfu/ml	4.7 × 106 cfu/ml
B. cepacia 25416	1.5 × 106 cfu/ml	1.0 × 106 cfu/ml
C. albicans 10231	3.2 × 106 cfu/ml	1.6 × 106 cfu/ml
A. niger 16404	4.0 × 105 cfu/ml	2.6 × 105 cfu/ml
TEST	ASSAY INTERVALS
ORGANISMS	48 HRS	7 D	14 D	21 D	28 D
USE LEVEL: 0.5%
Staph. aureus 6538	1.4E5	<10	<10	<10	<10
E. coli 8739	6.6E3	<10	<10	<10	<10
P. aeruginosa 9027	<10	<10	<10	<10	<10
B. cepacia 25416	4.0E4	<10	<10	<10	<10
C. albicans 10231	>1E6	8.1E5	5.2E4	<10	>1E4
A. niger 16404	5.9E5	1.9E5	3.5E4	1.2E4	6.9E5
USE LEVEL: 1.0%
Staph. aureus 6538	<10	<10	<10	<10	<10
E. coli 8739	<10	<10	<10	<10	<10
P. aeruginosa 9027	<10	<10	<10	<10	<10
B. cepacia 25416	<10	<10	<10	<10	<10
C. albicans 10231	3.4E5	<10	<10	<10	<10
A. niger 16404	6.5E5	2.4E4	1.2E3	9E1	>1E4

Example 3

ANTIMICROBIAL: 1,2-Octanediol/Phenoxyethanol (40/60)/1.5% BIT
PRODUCT BASE: Screening Emulsion
TEST
ORGANISMS	INOCULUM (0 hours)	REINOCULUM (21 days)
Staph aureus 6538	4.9 × 106 cfu/ml	2.6 × 106 cfu/ml
E. coli 8739	5.6 × 106 cfu/ml	4.3 × 106 cfu/ml
P. aeruginosa 9027	3.1 × 106 cfu/ml	3.2 × 106 cfu/ml
B. cepacia 25416	2.7 × 106 cfu/ml	1.8 × 106 cfu/ml
C. albicans 10231	4.2 × 106 cfu/ml	1.7 × 107 cfu/ml
A. niger 16404	1.9 × 105 cfu/ml	4.0 × 105 cfu/ml
TEST	ASSAY INTERVALS
ORGANISMS	48 HRS	7 D	14 D	21 D	28 D
USE LEVEL: 0.67% (100 ppm BIT)
Staph. aureus 6538	<10	<10	<10	<10	<10
E. coli 8739	<10	<10	<10	<10	<10
P. aeruginosa 9027	<10	<10	<10	<10	<10
B. cepacia 25416	<10	<10	<10	<10	<10
C. albicans 10231	<10	<10	<10	<10	<10
A. niger 16404	<10	<10	<10	<10	<10
USE LEVEL: 1.33% (200 ppm BIT)
Staph. aureus 6538	<10	<10	<10	<10	<10
E. coli 8739	<10	<10	<10	<10	<10
P. aeruginosa 9027	<10	<10	<10	<10	<10
B. cepacia 25416	<10	<10	<10	<10	<10
C. albicans 10231	<10	<10	<10	<10	<10
A. niger 16404	<10	<10	<10	<10	<10

Example 4

ANTIMICROBIAL: 1,2-Octanediol/Phenoxyethanol (40/60)/1.5% BIT
PRODUCT BASE: Nonionic Emulsion
TEST
ORGANISMS	INOCULUM (0 hours)	REINOCULUM (21 days)
Staph aureus 6538	1.2 × 106 cfu/ml	3.7 × 106 cfu/ml
E. coli 8739	3.2 × 106 cfu/ml	3.1 × 106 cfu/ml
P. aeruginosa 9027	3.0 × 106 cfu/ml	4.6 × 106 cfu/ml
B. cepacia 25416	6.0 × 105 cfu/ml	3.2 × 106 cfu/ml
C. albicans 10231	2.8 × 106 cfu/ml	2.4 × 106 cfu/mml
A. niger 16404	7.0 × 105 cfu/ml	4.0 × 105 cfu/ml
TEST	ASSAY INTERVALS
ORGANISMS	48 HRS	7 D	14 D	21 D	28 D
USE LEVEL: 0.67% (100 ppm BIT)
Staph. aureus 6538	<10	<10	<10	<10	<10
E. coli 8739	<10	<10	<10	<10	<10
P. aeruginosa 9027	<10	<10	<10	<10	<10
B. cepacia 25416	<10	<10	<10	<10	<10
C. albicans 10231	<10	<10	<10	<10	<10
A. niger 16404	3E1	<10	<10	<10	<10
USE LEVEL: 1.33% (200 ppm BIT)
Staph. aureus 6538	<10	<10	<10	<10	<10
E. coli 8739	<10	<10	<10	<10	<10
P. aeruginosa 9027	<10	<10	<10	<10	<10
B. cepacia 25416	<10	<10	<10	<10	<10
C. albicans 10231	<10	<10	<10	<10	<10
A. niger 16404	<10	<10	<10	<10	<10

Example 5

ANTIMICROBIAL: 1,2-Octanediol/Phenoxyethanol (40/60)/1.5% BIT
PRODUCT BASE: Screening Emulsion
TEST
ORGANISMS	INOCULUM (0 hours)	REINOCULUM (21 days)
Staph aureus 6538	3.7 × 106 cfu/ml	2.9 × 106 cfu/ml
E. coli 8739	3.1 × 106 cfu/ml	5.4 × 106 cfu/ml
P. aeruginosa 9027	4.6 × 106 cfu/ml	3.8 × 106 cfu/ml
B. cepacia 25416	3.2 × 106 cfu/ml	2.9 × 106 cfu/ml
C. albicans 10231	2.4 × 106 cfu/ml	2.2 × 106 cfu/ml
A. niger 16404	4.0 × 105 cfu/ml	2.9 × 105 cfu/ml
TEST	ASSAY INTERVALS
ORGANISMS	48 HRS	7 D	14 D	21 D	28 D
USE LEVEL: 0.25% (37.5 ppm BIT)
Staph. aureus 6538	<10	<10	<10	<10	<10
E. coli 8739	<10	<10	<10	<10	<10
P. aeruginosa 9027	<10	<10	<10	<10	<10
B. cepacia 25416	<10	<10	<10	<10	<10
C. albicans 10231	7.1E2	<10	<10	<10	<10
A. niger 16404	4.2E4	3.4E3	1.2E2	2E1	6.7E2
USE LEVEL: 0.5% (75 ppm BIT)
Staph. aureus 6538	<10	<10	<10	<10	<10
E. coli 8739	<10	<10	<10	<10	<10
P. aeruginosa 9027	<10	<10	<10	<10	<10
B. cepacia 25416	<10	<10	<10	<10	<10
C. albicans 10231	<10	<10	<10	<10	<10
A. niger 16404	<10	<10	<10	<10	2E1 (replate <10)

Example 6

ANTIMICROBIAL: 1,2-Octanediol/Phenoxyethanol (40/60)/1.5% BIT
PRODUCT BASE: Nonionic Emulsion
TEST
ORGANISMS	INOCULUM (0 hours)	REINOCULUM (21 days)
Staph aureus 6538	4.9 × 106 cfu/ml	4.8 × 106 cfu/ml
E. coli 8739	3.5 × 106 cfu/ml	3.1 × 106 cfu/ml
P. aeruginosa 9027	4.0 × 106 cfu/ml	3.0 × 106 cfu/ml
B. cepacia 25416	4.0 × 106 cfu/ml	2.2 × 106 cfu/ml
C. albicans 10231	3.5 × 106 cfu/ml	8.0 × 105 cfu/ml
A. niger 16404	2.7 × 106 cfu/ml	1.8 × 105 cfu/ml
TEST	ASSAY INTERVALS
ORGANISMS	48 HRS	7 D	14 D	21 D	28 D
USE LEVEL: 0.25% (37.5 ppm BIT)
Staph. aureus 6538	2E1	<10	<10	<10	<10
E. coli 8739	<10	<10	<10	<10	<10
P. aeruginosa 9027	<10	<10	<10	<10	<10
B. cepacia 25416	2E1	<10	<10	<10	<10
C. albicans 10231	>1E6	7.2E2	1E2	<10	>1E4
A. niger 16404	3.9E5	2.4E5	1.9E5	1.6E5	2.5E5
USE LEVEL: 0.50% (75 ppm BIT)
Staph. aureus 6538	<10	<10	<10	<10	<10
E. coli 8739	<10	<10	<10	<10	<10
P. aeruginosa 9027	<10	<10	<10	<10	<10
B. cepacia 25416	<10	<10	<10	<10	<10
C. albicans 10231	<10	<10	<10	<10	<10
A. niger 16404	4.4E4	2E3	5E1	<10	3.5E3

Example 7

ANTIMICROBIAL: 1,2-Octanediol/Phenoxyethanol (40/60)/1.5% BIT
PRODUCT BASE: Screening Emulsion
TEST
ORGANISMS	INOCULUM (0 hours)	REINOCULUM (21 days)
Staph aureus 6538	3.6 × 106 cfu/ml	2.8 × 106 cfu/ml
E. coli 8739	5.8 × 106 cfu/ml	3.5 × 106 cfu/ml
P. aeruginosa 9027	4.0 × 106 cfu/ml	3.2 × 106 cfu/ml
B. cepacia 25416	3.0 × 106 cfu/ml	1.8 × 106 cfu/ml
C. albicans 10231	2.7 × 106 cfu/ml	1.7 × 106 cfu/ml
A. niger 16404	1.3 × 106 cfu/ml	4.9 × 105 cfu/ml
TEST	ASSAY INTERVALS
ORGANISMS	48 HRS	7 D	14 D	21 D	28 D
USE LEVEL: 0.50% (75 ppm BIT)
Staph. aureus 6538	<10	<10	<10	<10	<10
E. coli 8739	<10	<10	<10	<10	<10
P. aeruginosa 9027	<10	<10	<10	<10	<10
B. cepacia 25416	<10	<10	<10	<10	<10
C. albicans 10231	<10	<10	<10	<10	<10
A. niger 16404	<10	<10	<10	<10	<10
USE LEVEL: 0.67% (100 ppm BIT)
Staph. aureus 6538	<10	<10	<10	<10	<10
E. coli 8739	<10	<10	<10	<10	<10
P. aeruginosa 9027	<10	<10	<10	<10	<10
B. cepacia 25416	<10	<10	<10	<10	<10
C. albicans 10231	<10	<10	<10	<10	<10
A. niger 16404	<10	<10	<10	<10	<10

Example 8

ANTIMICROBIAL: 1,2-Octanediol/Phenoxyethanol (40/60)/2.5% BIT
PRODUCT BASE: Screening Emulsion
TEST
ORGANISMS	INOCULUM (0 hours)	REINOCULUM (21 days)
Staph aureus 6538	3.6 × 106 cfu/ml	2.8 × 106 cfu/ml
E. coli 8739	5.8 × 106 cfu/ml	3.5 × 106 cfu/ml
P. aeruginosa 9027	4.0 × 106 cfu/mml	3.2 × 106 cfu/ml
B. cepacia 25416	3.0 × 106 cfu/ml	1.8 × 106 cfu/ml
C. albicans 10231	2.7 × 106 cfu/ml	1.7 × 106 cfu/ml
A. niger 16404	1.3 × 106 cfu/ml	4.9 × 105 cfu/ml
TEST	ASSAY INTERVALS
ORGANISMS	48 HRS	7 D	14 D	21 D	28 D
USE LEVEL: 0.3% (75 ppm BIT)
Staph. aureus 6538	<10	<10	<10	<10	<10
E. coli 8739	<10	<10	<10	<10	<10
P. aeruginosa 9027	<10	<10	<10	<10	<10
B. cepacia 25416	<10	<10	<10	<10	<10
C. albicans 10231	5.8E3	2E1	<10	<10	<10
A. niger 16404	1.8E2	<10	<10	<10	<10
USE LEVEL: 0.4% (100 ppm BIT)
Staph. aureus 6538	<10	<10	<10	<10	<10
E. coli 8739	<10	<10	<10	<10	<10
P. aeruginosa 9027	<10	<10	<10	<10	<10
B. cepacia 25416	<10	<10	<10	<10	<10
C. albicans 10231	<10	<10	<10	<10	<10
A. niger 16404	<10	<10	<10	<10	<10

Example 9

ANTIMICROBIAL: 1,2-Octanediol/Phenoxyethanol (40/60)/1.5% BIT
PRODUCT BASE: Nonionic Emulsion
TEST
ORGANISMS	INOCULUM (0 hours)	REINOCULUM (21 days)
Staph aureus 6538	3.0 × 106 cfu/ml	2.8 × 106 cfu/ml
E. coli 8739	5.8 × 106 cfu/ml	3.5 × 106 cfu/ml
P. aeruginosa 9027	4.0 × 106 cfu/ml	3.2 × 106 cfu/ml
B. cepacia 25416	3.0 × 106 cfu/ml	1.8 × 106 cfu/ml
C. albicans 10231	2.7 × 106 cfu/ml	1.7 × 106 cfu/ml
A. niger 16404	1.3 × 106 cfu/ml	4.9 × 105 cfu/ml
TEST	ASSAY INTERVALS
ORGANISMS	48 HRS	7 D	14 D	21 D	28 D
USE LEVEL: 0.50% (75 ppm BIT)
Staph. aureus 6538	<10	<10	<10	<10	<10
E. coli 8739	<10	<10	<10	<10	<10
P. aeruginosa 9027	<10	<10	<10	<10	<10
B. cepacia 25416	<10	<10	<10	<10	<10
C. albicans 10231	<10	<10	<10	<10	<10
A. niger 16404	8E1	<10	<10	<10	<10
USE LEVEL: 0.67% (100 ppm BIT)
Staph. aureus 6538	<10	<10	<10	<10	<10
E. coli 8739	<10	<10	<10	<10	<10
P. aeruginosa 9027	<10	<10	<10	<10	<10
B. cepacia 25416	<10	<10	<10	<10	<10
C. albicans 10231	<10	<10	<10	<10	<10
A. niger 16404	<10	<10	<10	<10	<10

Example 10

ANTIMICROBIAL: 1,2-Octanediol/Phenoxyethanol (40/60)/2.5% BIT
PRODUCT BASE: Nonionic Emulsion
TEST
ORGANISMS	INOCULUM (0 hours)	REINOCULUM (21 days)
Staph aureus 6538	3.0 × 106 cfu/ml	2.8 × 106 cfu/ml
E. coli 8739	5.8 × 106 cfu/ml	3.5 × 106 cfu/ml
P. aeruginosa 9027	4.0 × 106 cfu/ml	3.2 × 106 cfu/ml
B. cepacia 25416	2.7 × 106 cfu/ml	1.8 × 106 cfu/ml
C. albicans 10231	2.7 × 106 cfu/ml	1.7 × 106 cfu/ml
A. niger 16404	1.3 × 106 cfu/ml	4.9 × 105 cfu/ml
TEST	ASSAY INTERVALS
ORGANISMS	48 HRS	7 D	14 D	21 D	28 D
USE LEVEL: 0.30% (75 ppm BIT)
Staph. aureus 6538	<10	<10	<10	<10	<10
E. coli 8739	<10	<10	<10	<10	<10
P. aeruginosa 9027	<10	<10	<10	<10	<10
B. cepacia 25416	<10	<10	<10	<10	<10
C. albicans 10231	<10	<10	<10	<10	<10
A. niger 16404	1E4	8.6E2	2.1E2	3E1	8.3E2
USE LEVEL: 0.40% (100 ppm BIT)
Staph. aureus 6538	<10	<10	<10	<10	<10
E. coli 8739	<10	<10	<10	<10	<10
P. aeruginosa 9027	<10	<10	<10	<10	<10
B. cepacia 25416	<10	<10	<10	<10	<10
C. albicans 10231	<10	<10	<10	<10	<10
A. niger 16404	1E1	<10	<10	<10	<10

Example 11

ANTIMICROBIAL: 1,2-Octanediol/Phenoxyethanol
(40/60), 6% sorbic acid
PRODUCT BASE: Nonionic Emulsion
TEST
ORGANISMS	INOCULUM (0 hours)	REINOCULUM (21 days)
Staph aureus 6538	1.3 × 106 cfu/ml	8.0 × 106 cfu/ml
E. coli 8739	3.9 × 106 cfu/ml	4.8 × 106 cfu/ml
P. aeruginosa 9027	2.5 × 106 cfu/ml	4.7 × 106 cfu/ml
B. cepacia 25416	1.5 × 106 cfu/ml	1.0 × 106 cfu/ml
C. albicans 10231	3.2 × 106 cfu/ml	1.6 × 106 cfu/ml
A. niger 16404	4.0 × 105 cfu/ml	2.6 × 105 cfu/ml
TEST	ASSAY INTERVALS
ORGANISMS	48 HRS	7 D	14 D	21 D	28 D
USE LEVEL: 0.5%
Staph. aureus 6538	1.1E2	<10	<10	<10	<10
E. coli 8739	<10	<10	<10	<10	<10
P. aeruginosa 9027	<10	<10	<10	<10	<10
B. cepacia 25416	<10	<10	8E3	7E4	1.1E5
C. albicans 10231	>1E6	3.1E4	<10	<10	>1E4
A. niger 16404	8.3E5	4E1	<10	<10	1E1
USE LEVEL: 1.0%
Staph. aureus 6538	<10	<10	<10	<10	<10
E. coli 8739	<10	<10	<10	<10	<10
P. aeruginosa 9027	<10	<10	<10	<10	<10
B. cepacia 25416	<10	<10	<10	<10	<10
C. albicans 10231	1.2E4	<10	<10	<10	<10
A. niger 16404	3E5	<10	<10	<10	<10

Example 12

ANTIMICROBIAL: 1,2-Octanediol/Phenoxyethanol
(40/60), 6% sorbic acid
PRODUCT BASE: Nonionic Emulsion
TEST
ORGANISMS	INOCULUM (0 hours)	REINOCULUM (21 days)
Staph aureus 6538	6.9 × 106 cfu/ml	1.8 × 106 cfu/ml
E. coli 8739	7.8 × 106 cfu/ml	3.5 × 106 cfu/ml
P. aeruginosa 9027	5.1 × 106 cfu/ml	1.3 × 106 cfu/ml
B. cepacia 25416	2.2 × 106 cfu/ml	7.0 × 106 cfu/ml
C. albicans 10231	3.7 × 106 cfu/ml	6.0 × 107 cfu/ml
A. niger 16404	1.8 × 105 cfu/ml	8.0 × 105 cfu/ml
TEST	ASSAY INTERVALS
ORGANISMS	48 HRS	7 D	14 D	21 D	28 D
USE LEVEL: 0.50%
Staph. aureus 6538	1E1	<10	<10	<10	<10
E. coli 8739	6E1	<10	<10	<10	<10
P. aeruginosa 9027	1E2	<10	<10	<10	<10
B. cepacia 25416	5.8E4	<10	<10	<10	<10
C. albicans 10231	>1E6	1.7E5	2E1	<10	>1E4
A. niger 16404	1E5	5.8E4	3E4	6E3	3.9E5
USE LEVEL: 1.0%
Staph. aureus 6538	<10	<10	<10	<10	<10
E. coli 8739	<10	<10	<10	<10	<10
P. aeruginosa 9027	<10	<10	<10	<10	<10
B. cepacia 25416	<10	<10	<10	<10	<10
C. albicans 10231	<10	<10	<10	<10	<10
A. niger 16404	3E4	<10	<10	<10	<10

Example 13

ANTIMICROBIAL: 1,2-Octanediol/Phenoxyethanol
(40/60), 6% sorbic acid
PRODUCT BASE: Nonionic Emulsion
TEST
ORGANISMS	INOCULUM (0 hours)	REINOCULUM (21 days)
Staph aureus 6538	6.9 × 106 cfu/ml	1.8 × 106 cfu/ml
E. coli 8739	7.8 × 106 cfu/ml	3.5 × 106 cfu/ml
P. aeruginosa 9027	5.1 × 106 cfu/ml	1.3 × 106 cfu/ml
B. cepacia 25416	2.2 × 106 cfu/ml	7.0 × 106 cfu/ml
C. albicans 10231	3.7 × 106 cfu/ml	6.0 × 107 cfu/ml
A. niger 16404	1.8 × 105 cfu/ml	8.0 × 105 cfu/ml
TEST	ASSAY INTERVALS
ORGANISMS	48 HRS	7 D	14 D	21 D	28 D
USE LEVEL: 0.5%
Staph. aureus 6538	<10	<10	<10	<10	<10
E. coli 8739	<10	<10	<10	<10	<10
P. aeruginosa 9027	<10	<10	<10	<10	<10
B. cepacia 25416	8E1	<10	<10	<10	2E1
C. albicans 10231	>1E6	1.4E4	<10	<10	<10
A. niger 16404	2.1E5	5.5E4	8E3	3E3	3.4E5
USE LEVEL: 1.0%
Staph. aureus 6538	<10	<10	<10	<10	<10
E. coli 8739	<10	<10	<10	<10	<10
P. aeruginosa 9027	<10	<10	<10	<10	<10
B. cepacia 25416	<10	<10	<10	<10	<10
C. albicans 10231	<10	<10	<10	<10	<10
A. niger 16404	8E3	<10	<10	<10	<10

Example 14

ANTIMICROBIAL: 1,2-Octanediol/Phenoxyethanol
(40/60), 6% sorbic acid
PRODUCT BASE: Nonionic Emulsion
TEST
ORGANISMS	INOCULUM (0 hours)	REINOCULUM (21 days)
Staph aureus 6538	6.9 × 106 cfu/ml	1.8 × 106 cfu/ml
E. coli 8739	7.8 × 106 cfu/ml	3.5 × 106 cfu/ml
P. aeruginosa 9027	5.1 × 106 cfu/ml	1.3 × 106 cfu/ml
B. cepacia 25416	2.2 × 106 cfu/ml	7.0 × 106 cfu/ml
C. albicans 10231	3.7 × 106 cfu/ml	6.0 × 107 cfu/ml
A. niger 16404	1.8 × 105 cfu/ml	8.0 × 105 cfu/ml
TEST	ASSAY INTERVALS
ORGANISMS	48 HRS	7 D	14 D	21 D	28 D
USE LEVEL: 0.50%
Staph. aureus 6538	<10	<10	<10	<10	<10
E. coli 8739	<10	<10	<10	<10	<10
P. aeruginosa 9027	<10	<10	<10	<10	<10
B. cepacia 25416	<10	<10	<10	<10	<10
C. albicans 10231	>1E6	2E4	<10	<10	>1E4
A. niger 16404	1.8E5	1.1E5	1.2E3	2E2	>1E4
USE LEVEL: 1.0%
Staph. aureus 6538	<10	<10	<10	<10	<10
E. coli 8739	<10	<10	<10	<10	<10
P. aeruginosa 9027	<10	<10	<10	<10	<10
B. cepacia 25416	<10	<10	<10	<10	<10
C. albicans 10231	<10	<10	<10	<10	<10
A. niger 16404	6E3	<10	<10	<10	7E1

Example 15

ANTIMICROBIAL: 1,2-Octanediol/Phenoxyethanol (40/60)
PRODUCT BASE: Screening Emulsion
TEST
ORGANISMS	INOCULUM (0 hours)	REINOCULUM (21 days)
Staph aureus 6538	2.9 × 106 cfu/ml	2.5 × 105 cfu/ml
E. coli 8739	4.7 × 106 cfu/ml	3.4 × 106 cfu/ml
P. aeruginosa 9027	4.9 × 106 cfu/ml	1.2 × 106 cfu/ml
B. cepacia 25416	5.3 × 106 cfu/ml	1.1 × 106 cfu/ml
C. albicans 10231	1.0 × 106 cfu/ml	1.1 × 106 cfu/ml
A. niger 16404	7.0 × 105 cfu/ml	4.4 × 105 cfu/ml
TEST	ASSAY INTERVALS
ORGANISMS	48 HRS	7 D	14 D	21 D	28 D
USE LEVEL: 0.5%
Staph. aureus 6538	7E1	<10	<10	<10	<10
E. coli 8739	<10	<10	<10	<10	<10
P. aeruginosa 9027	<10	<10	<10	<10	<10
B. cepacia 25416	<10	<10	<10	<10	<10
C. albicans 10231	4E4	<10	<10	<10	1E1
A. niger 16404	2.3E5	2.3E4	2.5E2	2E1	>1E4
USE LEVEL: 1.0%
Staph. aureus 6538	<10	<10	<10	<10	<10
E. coli 8739	<10	<10	<10	<10	<10
P. aeruginosa 9027	<10	<10	<10	<10	<10
B. cepacia 25416	<10	<10	<.10	<10	<10
C. albicans 10231	<10	<10	<10	<10	<10
A. niger 16404	3E4	<10	<10	<10	<10

Example 16

ANTIMICROBIAL: 20 Pentanediol/20 Hexanediol/
20 Octanediol/40 Phenoxyethanol
PRODUCT BASE: Screening Emulsion
TEST
ORGANISMS	INOCULUM (0 hours)	REINOCULUM (21 days)
Staph aureus 6538	2.5 × 106 cfu/ml	2.5 × 106 cfu/ml
E. coli 8739	6.0 × 106 cfu/ml	2.9 × 106 cfu/ml
P. aeruginosa 9027	5.7 × 106 cfu/ml	2.3 × 106 cfu/ml
B. cepacia 25416	3.4 × 106 cfu/ml	1.5 × 106 cfu/ml
C. albicans 10231	2.9 × 106 cfu/ml	1.1 × 106 cfu/mkl
A. niger 16404	5.1 × 105 cfu/ml	2.8 × 105 cfu/ml
TEST	ASSAY INTERVALS
ORGANISMS	48 HRS	7 D	14 D	21 D	28 D
USE LEVEL: 0.25%
Staph. aureus 6538	1.1E6	1.6E3	<10	<10	>1E4
E. coli 8739	2E2	<10	<10	<10	<10
P. aeruginosa 9027	3E1	3E3	4E1	1E2	>1E4
B. cepacia 25416	>1E6	>1E6	4.3E5	1.8E5	>1E6
C. albicans 10231	7.9E5	1.2E5	4.1E2	2.2E2	>1E4
A. niger 16404	1.8E5	3.2E5	3.3E5	1.4E5	5.1E5
USE LEVEL: 0.50%
Staph. aureus 6538	9.8E4	<10	<10	<10	<10
E. coli 8739	<10	<10	<10	<10	<10
P. aeruginosa 9027	<10	<10	<10	<10	<10
B. cepacia 25416	2.7E5	<10	<10	<10	<10
C. albicans 10231	3.8E5	2E2	<10	<10	8E1
A. niger 16404	2.6E5	3.3E5	1.7E3	8E2	>1E4

Example 17

ANTIMICROBIAL: 20 Pentanediol/20 Hexanediol/
20 Octanediol/40 Phenoxyethanol
PRODUCT BASE: Nonionic Emulsion
TEST
ORGANISMS	INOCULUM (0 hours)	REINOCULUM (21 days)
Staph aureus 6538	2.5 × 106 cfu/ml	2.5 × 106 cfu/ml
E. coli 8739	6.0 × 106 cfu/ml	2.9 × 106 cfu/ml
P. aeruginosa 9027	5.7 × 106 cfu/ml	2.3 × 106 cfu/ml
B. cepacia 25416	3.4 × 106 cfu/ml	1.5 × 106 cfu/ml
C. albicans 10231	2.9 × 106 cfu/ml	1.1 × 106 cfu/mkl
A. niger 16404	5.1 × 105 cfu/ml	2.8 × 105 cfu/ml
TEST	ASSAY INTERVALS
ORGANISMS	48 HRS	7 D	14 D	21 D	28 D
USE LEVEL: 0.5%
Staph. aureus 6538	2.6E5	<10	<10	<10	<10
E. coli 8739	2.2E4	<10	<10	<10	<10
P. aeruginosa 9027	<10	<10	<10	<10	<10
B. cepacia 25416	2.6E5	6E3	<10	<10	2.9E3
C. albicans 10231	>1E6	>1E6	4.8E4	7.1E2	9.3E5
A. niger 16404	6.8E5	4.8E5	1.4E5	>1E4	6.2E5
USE LEVEL: 1.0%
Staph. aureus 6538	<10	<10	<10	<10	<10
E. coli 8739	<10	<10	<10	<10	<10
P. aeruginosa 9027	<10	<10	<10	<10	<10
B. cepacia 25416	1E2	<10	<10	<10	<10
C. albicans 10231	>1E6	2.8E4	<10	<10	<10
A. niger 16404	3.8E5	3.5E5	1.3E4	2.9E2	5.3E4

Example 18

ANTIMICROBIAL: 20 Pentanediol/20 Hexanediol/
20 Octanediol/40 Phenoxyethanol
PRODUCT BASE: Screening Emulsion
TEST
ORGANISMS	INOCULUM (0 hours)	REINOCULUM (21 days)
Staph aureus 6538	1.8 × 106 cfu/ml	1.0 × 106 cfu/ml
E. coli 8739	3.5 × 106 cfu/ml	3.6 × 106 cfu/ml
P. aeruginosa 9027	1.3 × 106 cfu/ml	2.9 × 106 cfu/ml
B. cepacia 25416	7.0 × 106 cfu/ml	3.0 × 106 cfu/ml
C. albicans 10231	6.0 × 105 cfu/ml	2.1 × 106 cfu/ml
A. niger 16404	8.0 × 105 cfu/ml	2.8 × 105 cfu/ml
TEST	ASSAY INTERVALS
ORGANISMS	48 HRS	7 D	14 D	21 D	28 D
USE LEVEL: 0.5%
Staph. aureus 6538	1.3E4	<10	<10	<10	<10
E. coli 8739	<10	<10	<10	<10	<10
P. aeruginosa 9027	<10	<10	<10	<10	<10
B. cepacia 25416	1.9E5	<10	<10	<10	<10
C. albicans 10231	3E5	3.3E3	<10	<10	9.7E2
A. niger 16404	6.8E5	6E4	3.3E4	1.1E4	6E4
USE LEVEL: 1.0%
Staph. aureus 6538	<10	<10	<10	<10	<10
E. coli 8739	<10	<10	<10	<10	<10
P. aeruginosa 9027	<10	<10	<10	<10	<10
B. cepacia 25416	<10	<10	<10	<10	<10
C. albicans 10231	3.8E2	<10	<10	<10	<10
A. niger 16404	4.9E4	1.4E4	1.7E2	1.3E2	6.7E3

Example 19

ANTIMICROBIAL: 1,2-Octanediol/Phenoxyethanol (40/60), 1.25% IPBC
PRODUCT BASE: Screening Emulsion
TEST
ORGANISMS	INOCULUM (0 hours)	REINOCULUM (21 days)
Staph aureus 6538	3.6 × 106 cfu/ml	1.6 × 106 cfu/ml
E. coli 8739	4.0 × 106 cfu/ml	2.2 × 106 cfu/ml
P. aeruginosa 9027	4.4 × 106 cfu/ml	1.7 × 106 cfu/ml
B. cepacia 25416	3.0 × 106 cfu/ml	1.7 × 106 cfu/ml
C. albicans 10231	4.2 × 106 cfu/ml	9.3 × 105 cfu/ml
A. niger 16404	9.0 × 105 cfu/ml	2.6 × 105 cfu/ml
TEST	ASSAY INTERVALS
ORGANISMS	48 HRS	7 D	14 D	21 D	28 D
USE LEVEL: 1.0%
Staph. aureus 6538	<10	<10	<10	<10	<10
E. coli 8739	<10	<10	<10	<10	<10
P. aeruginosa 9027	<10	<10	<10	<10	<10
B. cepacia 25416	<10	<10	<10	<10	<10
C. albicans 10231	<10	<10	<10	<10	<10
A. niger 16404	<10	<10	<10	<10	<10
USE LEVEL: 1.8%
Staph. aureus 6538	<10	<10	<10	<10	<10
E. coli 8739	<10	<10	<10	<10	<10
P. aeruginosa 9027	<10	<10	<10	<10	<10
B. cepacia 25416	<10	<10	<10	<10	<10
C. albicans 10231	<10	<10	<10	<10	<10
A. niger 16404	<10	<10	<10	<10	<10

Claims

1. An antimicrobial composition which is active against gram-negative bacteria selected from the group consisting of E. coli and P. aeruginosa, gram-positive Staph aureus bacteria, C. albicans, yeast, B. cepacia and A. niger mold spores, said antimicrobial composition consisting essentially of, by wt.: (a) 40-60% of a 1,2-diol selected from the group consisting of 1,2-pentanediol, 1,2-hexanediol, 1,2-octanediol and mixtures thereof,(b) 40-60% phenoxyethanol; and(c) 0-10% of a co-biocide selected from the group consisting of sorbic acid, benzoic acid, dibromodicyanobutane, and 1,2-benzisothiazolin-3-one.

2. An antimicrobial composition according to claim 1 in which (c) is present and is sorbic acid.

3. An antimicrobial composition according to claim 1 wherein (a) is about 44% and (b) is about 56%.

4. An antimicrobial composition according to claim 2 wherein the sorbic acid is present in an amount of about 5-7% of the composition.

5. An antimicrobial composition of claim 1 wherein (a) is 41-42%, (b) is 52-53%; and (c) is sorbic acid at 5-7%.

6. An antimicrobial composition of claim 1 wherein (a) is present in an amount of 43.3%; (b) is present in an amount of 55.3%; and (c) is present in an amount of 1.4%.

7. An antimicrobial composition consisting essentially of, by weight, based on the total weight of (a) and (b): (a) 40-60% of a 1,2-diol selected from the group consisting of 1,2-pentanediol, 1,2-hexanediol, 1,2-octanediol and mixtures thereof;(b) 40-60% phenoxyethanol; and(c) 0-10% of a co-biocide selected from the group consisting of sorbic acid, benzoic acid, dibromodicyano-butane, 1,2-benzisothiazolin-3-one, and mixtures thereof,wherein said antimicrobial composition is active against at least one of E. coli, Staph aureus, P. aeruginosa, B. cepacia, C. albicans, and A. niger.

8. An antimicrobial composition according to claim 7 in which (c) is present and is sorbic acid.

9. An antimicrobial composition according to claim 8 wherein the sorbic acid is present in an amount of about 5-7% of the composition.

10. An antimicrobial composition according to claim 7 wherein (a) is about 40% and (b) is about 60%.

11. An antimicrobial composition according to claim 10 wherein (a) comprises 1,2-octanediol.

12. An antimicrobial composition according to claim 10 wherein a co-biocide is present.

13. An antimicrobial composition according to claim 12 wherein the co-biocide is sorbic acid.

14. An antimicrobial composition according to claim 13 wherein the sorbic acid is present in an amount of about 5-7%.